Key Insights

Highlights

Treatment Research

1 treatments under study, led by Inclisiran Sodium 300 Mg Equivalent To 284 Mg Inclisiran In 15 Ml

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Research Network

Common Treatments

  • Inclisiran Sodium 300 Mg Equivalent To 284 Mg Inclisiran In 15 Ml1

Active Sponsors

  • Novartis1
  • University of California, San Diego1

Top Investigators

Related Conditions

  • Primary Prevention1
  • Cardiometabolic Syndrome1
  • Drug Interactions1

Activity Timeline